Literature DB >> 33528031

Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma.

Ioanna Xagoraris1, Theodoros P Vassilakopoulos2, Elias Drakos3, Maria K Angelopoulou2, Fotios Panitsas2, Nikolas Herold4,5, L Jeffrey Medeiros6, Xanthoula Giakoumis7, Gerassimos A Pangalis2,7, George Z Rassidakis1,6.   

Abstract

The expression patterns and prognostic significance of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) protein in the neoplastic Hodgkin and Reed Sternberg (HRS) cells of Hodgkin lymphoma (HL) were investigated in a cohort of 154 patients with HL treated with standard regimens. SAMHD1 expression was assessed by immunohistochemistry using diagnostic lymph node biopsies obtained prior to treatment. Using an arbitrary 20% cut-off, SAMHD1 was positive in HRS cells of 48/154 (31·2%) patients. SAMHD1 expression was not associated with clinicopathologic parameters, such as age, gender, stage or histologic subtype. In 125 patients with a median follow-up of 90 months (7-401 months), SAMHD1 expression in HRS cells significantly correlated with inferior freedom from progression (FFP) (P = 0·025), disease-specific survival (DSS) (P = 0·013) and overall survival (OS) (P = 0·01). Importantly, in multivariate models together with disease stage, histology subtype and type of treatment as covariates, SAMHD1 expression retained an independent significant association with unfavourable FFP (P = 0·005) as well as DSS (P = 0·022) and OS (P = 0·018). These findings uncover the significance of a novel, adverse prognostic factor in HL that may have therapeutic implications since SAMHD1 inhibitors are now available for clinical use.
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  Hodgkin lymphoma; SAMHD1; prognosis

Year:  2021        PMID: 33528031     DOI: 10.1111/bjh.17352

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells.

Authors:  Tamara Rothenburger; Dominique Thomas; Yannick Schreiber; Paul R Wratil; Tamara Pflantz; Kirsten Knecht; Katie Digianantonio; Joshua Temple; Constanze Schneider; Hanna-Mari Baldauf; Katie-May McLaughlin; Florian Rothweiler; Berna Bilen; Samira Farmand; Denisa Bojkova; Rui Costa; Nerea Ferreirós; Gerd Geisslinger; Thomas Oellerich; Yong Xiong; Oliver T Keppler; Mark N Wass; Martin Michaelis; Jindrich Cinatl
Journal:  J Exp Clin Cancer Res       Date:  2021-10-12

2.  Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types.

Authors:  Eudald Felip; Lucía Gutiérrez-Chamorro; Maica Gómez; Edurne Garcia-Vidal; Margarita Romeo; Teresa Morán; Laura Layos; Laia Pérez-Roca; Eva Riveira-Muñoz; Bonaventura Clotet; Pedro Luis Fernandez; Ricard Mesía; Anna Martínez-Cardús; Ester Ballana; Mireia Margelí
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

Review 3.  SAMHD1 in cancer: curse or cure?

Authors:  Kerstin Schott; Catharina Majer; Alla Bulashevska; Liam Childs; Mirko H H Schmidt; Krishnaraj Rajalingam; Markus Munder; Renate König
Journal:  J Mol Med (Berl)       Date:  2021-09-04       Impact factor: 4.599

4.  Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas.

Authors:  Ioanna Xagoraris; Pedro Farrajota Neves da Silva; Georgia Kokaraki; Konstantina Stathopoulou; Björn Wahlin; Anders Österborg; Nikolas Herold; Siok-Bian Ng; L Jeffrey Medeiros; Elias Drakos; Birgitta Sander; George Z Rassidakis
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

5.  SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study.

Authors:  Dingyun You; Shuai Zhang; Shan Yan; Yingying Ding; Chunxia Li; Xianshuo Cheng; Lin Wu; Weizhou Wang; Tao Zhang; Zhenhui Li; Yongwen He
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.